This link will take you to a Web site maintained by a third party who is solely responsible for its contents. ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc. provide this link as a service to Web site visitors. ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc. are not responsible for the privacy policy of any third party Web sites. We encourage you to read the privacy policy of every Web site you visit. Click CANCEL to return or OK to continue.
OKCancel
The information requested is intended for US healthcare professionals only. I am a healthcare professionalI am not a healthcare professional
The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "VIEW PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

View PDF Cancel

Don't show me this message again.

 

The SUCCEED Trial

Sarcoma Multi-Center Clinical Evaluation of the
Efficacy of Deforolimus

Welcome to the SUCCEED trial Web site where you will find information on SUCCEED: Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus. SUCCEED is a multinational, randomized, Phase 3, double-blind, placebo-controlled trial of oral deforolimus in patients diagnosed with metastatic soft-tissue or bone sarcomas.1

Deforolimus is an investigational agent and has not been approved by the US Food and Drug Administration (FDA) or regulatory agencies in any other country.

Please keep the SUCCEED trial in mind for your patients with metastatic sarcoma.

Refer a Patient


Reference: 1. ClinicalTrials.gov. Deforolimus (AP23573) in treatment of sarcoma — SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) study. http://www.clinicaltrials.gov/ct2/show/NCT00538239?
term=NCT00538239&rank=1. Accessed April 21, 2008.

What Is Deforolimus?

Learn more about this small molecule inhibitor of mTOR.

Learn More

Who Is Eligible?

Click here for key eligibility criteria.

Learn More

How Does the SUCCEED
Trial Work?

Click here for further information about the trial design.

Learn More



Home | Register for Updates | Contact Us | Privacy Policy | Terms of Use | Unsubscribe | Site Map

This site is intended for US healthcare professionals only. The use of deforolimus (AP23573, MK-8669) is limited to investigational trials.
There is no guarantee that its use will be approved by the US Food and Drug Administration.

This site is brought to you by ARIAD Pharmaceuticals, Inc. and Merck & Co., Inc.
© 2008 ARIAD Pharmaceuticals, Inc.
Copyright © 2008 Merck & Co., Inc. All rights reserved.

ARIADMERCK